AIkido Pharma Inc (AIKI)

[mining101]

How is that company called?

[nuclear profitz]

at what price is this offering?

[nssrr5]

Damn glad I didn’t get in.

[georgie18]

AIKI...80...in the P/M...Following the S1...Scaling in here in case the Earnings report is solid...Will add accordingly following the Earning Report on Wednesday...

https://www.otcmarkets.com/filing/html?id=14340728&guid=cBl6UqE6ed8dq8h

[starkd748]

it's only just begun 21milly share offering

[starkd748]

I hope you bought AVG$ today....You might get a decent price before it runs...

[Icanslim]

Yes I did, starkd.

[starkd748]

I hope you listened 21.6 milly share offering....

[Runners123]

Enjoy ride back up the selling has pretty muted dried up

[nssrr5]

Well damn there they are.

[nssrr5]

Waiting for .70s here

[Runners123]

Getting now, looks like way over sold

[nssrr5]

Getting close to taking a position here.

[Viewmont]

I was hopping they'd come up with some help with covid cure, with all the patents they've been releasing by HOTH and and AIKI.

[mick]

Alkido Pharma Inc (AIKI)
0.875 ? -0.0022 (-0.25%)
Volume: 1,281,393 @08/14/20 7:59:40 PM EDT
Bid Ask Day's Range
0.8602 0.9 0.88 - 0.919
AIKI Detailed Quote

[georgie18]

Next Earnings scheduled date is August 19...so will see what happens there...

[nssrr5]

Looking for an entry myself. I think this sees .70 range again soon.

[georgie18]

AIKI...886...Scaling back in on the Bullish Homing Pigeon Reversal Pattern to the Upside...Bollie Squeeze is Diverging as AIKI pierced the lower Bollie to the Downside...setting up a strong bouncer possibility here following the 2 Gap Down candles on the Oversold Williams...imo...we shall see...

As of August 5, 2020, there were 34,920,219 shares of the Company’s common stock issued and outstanding.

georgie18...08/11/2020
AIKI...$1.15...all out for now from my .70 range shares...on the $1.33 move ...Do not like the candle and too much risk to leave all that profit on the table...Watching for another entry as the Bollies are Squeezing...

Chart...http://schrts.co/ZKdsXsax

[weedtrader420]

woohoooooooooooo

[nssrr5]

Even more tempting...

[nssrr5]

This is getting pretty tempting.

[Viewmont]

NEW YORK, NY / ACCESSWIRE / August 10, 2020 / Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, announced today that the Company would be presenting at LD Micro's Zooming with LD on Tuesday, August 11th, 2020.

Robb Knie, Chief Executive Officer, will be presenting an overview of the company, as well as discussing recent developments and key highlights, including the company's just announced license to pursue the development of a breath-based COVID-19 mobile testing device.

The Hoth Therapeutics presentation will take place virtually over Zoom on Tuesday, August 11th, at 8 AM PDT.

To join the presentation, click here.
The password is HOTHwithLD

About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event). In 2015, LD Micro launched ldmicro.com as a portal to provide exclusive intraday information on the entire sector, including the first pure micro-cap index (LDMi) which covers stocks in North America with market capitalizations between $50 million to $300 million.

About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

SOURCE: Hoth Therapeutics, Inc.



View source version on accesswire.com:
https://www.accesswire.com/601064/Hoth-Therapeutics-to-Participate-in-LD-Micros-Zooming-with-LD-August-11th-8-AM-PDT

© Copyright 2020 ACCESSWIRE. All Rights Reserved.
Webinar: Put-Call Parity & Synthetics
Sponsored By : The Options Industry Council
Join OIC on Aug. 12 at 3:30 PM CST for a free webinar exploring the concept of put-call parity. We’ll discuss the definition of parity, cost of carry and arbitrage, as well as synthetic stocks, calls and puts. Register to reserve your spot today! Read More

Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
Nasdaq

[BluSkies]

NEWS!?

[mining101]

Source Target??

[weedtrader420]

*AIKI* $ ) $3 TARGET PRICE WOOHOOOOOOOOOOOOOOO

[mining101]

Good moves in the chart

[Viewmont]

LD Micro - Announces Preliminary List of Presenters for the LD-500
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

"For the first time in ten years, we were unable to host our mid-year conference, which caused us to dream up the LD 500," stated Chris Lahiji, President of LD Micro. "This will be our most ambitious event to date, expected to feature over 300 companies to more than 20,000 attendees. While the economy and financial world have been turned upside down, investor interest is as high as we have ever seen, and we will have something for everyone. Our "Zooming with LD" series has created some significant momentum that we plan to ride out till the big week."

REGISTER HERE

The preliminary list of presenting companies:

Acer Therapeutics
ACER
Acme United Corp
ACU
ADDvantage Technologies Group, Inc.
AEY
Adial Pharmaceuticals Inc.
ADIL
Advaxis
ADXS
Aehr Test Systems
AEHR
AIkido Pharma Inc.
AIKI
AIM ImmunoTech Inc.
AIM
Air Industries Group
AIRI
Akerna
KERN
Algernon Pharmaceuticals
AGNPF
Alimera Sciences
ALIM
Allot
ALLT
Alpine 4 Technologies
ALPP
American Shared Hospital Services
AMS
Amesite
PRIVATE
AnalytixInsight Inc.
ALY.V
Annovis Bio
ANVS
Antibe Therapeutics
ATE.V
Apollo Endosurgery, Inc.
APEN
Applied Energetics, Inc.
AERG
Aptorum Group Limited
APM
AquaBounty Technologies
AQB
Arch Therapeutics
ARTH
Artelo Biosciences, Inc.
ARTL
Assure Holdings
ARHH
Asure Software
ASUR
Atomera Incorporated
ATOM
Atossa Genetics
ATOS
Aurora Solar Technologies
ACU.V
AutoWeb, Inc.
AUTO
Avivagen
VIV.V
AYRO Inc
AYRO
Aytu BioScience Inc.
AYTU
AzurRx BioPharma, Inc.
AZRX
Ballard Power Systems Inc.
BLDP
Bel Fuse, Inc.
BELFA
BioCardia, Inc.
BCDA
Biocept, Inc.
BIOC
BioLargo, Inc.
BLGO
Biomerica
BMRA
BioSig Technologies
BSGM
BioSyent Inc.
RX.V
Blink Charging
BLNK
BlueCity
BLCT
Blueknight
BKEP
BOQI International Medical Inc.
BIMI
Bright Mountain Media
BMTM
C-Bond Systems
CBNT
Caladrius Biosciences, Inc.
CLBS
Calyxt, Inc.
CLXT
Camtek Ltd.
CAMT
Can-Fite BioPharma, Ltd.
CANF
Capstone Turbine Corporation
CPST
CEL-SCI Corporation
CVM
Cemtrex, Inc.
CETX
Chicken Soup for the Soul Entertainment, Inc.
CSSE
ChromaDex
CDXC
Cinedigm
CIDM
Citius Pharmaceuticals, Inc.
CTXR
CLPS Incorporation
CLPS
Conversion Labs
CVLB
Crown EK
CRKN
CynergisTek, Inc.
CTEK
Data443 Risk Mitigation
ATDS
Delcath Systems Inc.
DCTH
Digirad Corporation
DRAD
Digital Ally
DGLY
Dolphin Entertainment Inc.
DLPN
Driven
DRVD
electroCore
ECOR
Energous
WATT
Energy Focus, Inc.
EFOI
Energy Fuels
UUUU
Enthusiast Gaming
EGLX
EnviroLeach Technologies Inc.
EVLLF
Envision Solar
EVSI
Esports Entertainment Group
GMBL
Evogene
EVGN
Excellon Resources
EXLLF
Exro Technologies Inc.
XRO.CN
Foresight Autonomous Holdings Ltd.
FRSX
Fortress Biotech
FBIO
GAN Limited
GAN
Genasys Inc.
GNSS
Genprex, Inc.
GNPX
Gigatronics
GIGA
GOLO Mobile Inc.
GOLO.V
Greenbox POS
GRBX
Greenbrook TMS NeuroHealth Centers
GTMS.TO
GSI Technology
GSIT
Helius Medical
HSDT
Heritage Global, Inc.
HGBL
Hoth Therapeutics, Inc
HOTH
iCAD
ICAD
iClick Interactive
ICLK
Iconic Brands
ICNB
iConsumer Corp
RWRDP
Ideal Power
IPWR
IDEAYA Biosciences
IDYA
IEC Electronics
IEC
IMAC Holdings
IMAC
Immunovia AB
IMMVF
IMV Inc.
IMV
Indonesia Energy Corporation
INDO
InfuSystems
INFU
Inpixon
INPX
Intellicheck, Inc.
IDN
inTEST Corporation
INTT
Inuvo, Inc.
INUV
Issuer Direct Corporation
ISDR
Jerash Holdings
JRSH
Kandi Technologies
KNDI
Kindred Biosciences
KIN
Lantern Pharma
LTRN
Lexaria Bioscience Corp.
LXRP
LifeVantage
LFVN
LightPath Technologies
LPTH
Lightwave Logic
LWLG
Limbach Holdings, Inc.
LMB
Lineage Cell Therapeutics, Inc.
LCTX
LiveXLive Media, Inc.
LIVX
Lomiko Metals Inc.
LMR.V
Mace Security International, Inc.
MACE
Magal Security Systems Ltd.
MAGS
Mako Mining
MKO.V
Mama Mancini's
MMMB
Manitex International Inc
MNTX
Marrone Bio Innovations
MBII
Matinas
MTNB
Medallion Financial Corp.
MFIN
Medexus Pharmaceuticals Inc.
MDP.V
Meritage Hospitality
MHGU
Milestone Scientific
MLSS
Monaker Group
MKGI
MTBC, Inc.
MTBC
My Size Inc.
MYSZ
Myomo
MYO
NameSilo Technologies
URL.CN
Nanalysis Corp.
NSCI.V
Nano Dimension
NNDM
Nanotech Security Corp.
NTS.V
NanoViricides, Inc.
NNVC
Nemaura Medical
NMRD
NeoGenomics
NEO
Nephros, Inc.
NEPH
NervGen Pharma Corp.
NGENF
Neubase Therapeutics, Inc.
NBSE
Nova Leap Health Corp.
NLH.V
Oblong Inc.
OBLG
OncoSec Medical Incorporated
ONCS
OneSoft Solutions Inc.
OSS.V
OneStopSystems
OSS
OpSens Inc.
OPS.TO
Optex Systems Holdings
OPXS
Orion Energy Systems
OESX
PAVmed Inc.
PAVM
Paxmedica
PRIVATE
Performant
PFMT
Piedmont Lithium
PLL
POET Technologies Inc
PTK.V
Predictive Oncology Inc.
POAI
Profire Energy
PFIE
Protech Home Medical Corp.
PTQ.V
Quantum Computing Inc.
QUBT
Quest Patent Research Corporation
QPRC
Ra Medical Systems
RMED
RADA Electronic Industries Ltd
RADA
RadNet, Inc.
RDNT
Rekor Systems, Inc
REKR
Remark Holdings
MARK
Renesola Power
SOL
Salarius Pharmaceuticals
SLRX
Sangoma Technologies
STC
SG Blocks Inc.
SGBX
SharpSpring, Inc.
SHSP
ShiftPixy Inc.
PIXY
Slinger Bag
SLBG
Smith-Midland Corporation
SMID
Sono-Tek
SOTK
SRAX, Inc.
SRAX
Staffing 360 Solutions, Inc.
STAF
Summit Wireless Technologies
WISA
Super League Gaming, Inc.
SLGG
The Joint Chiropractic
JYNT
Theralink Technologies
OBMP
Thunderbird Entertainment
TBRD.V
Timber Pharmaceuticals
TMBR
Tinybeans
TNYYF
Titan Medical Inc.
TMDI
Tiziana Life Sciences PLC
TLSA
Tonix Pharmaceuticals
TNXP
Torchlight Energy Resources, Inc.
TRCH
Trxade Group
MEDS
Turtle Beach Corporation
HEAR
UGE International Ltd.
UGE.V
Unigold
UGDIF
Ur-Energy Inc.
URG
US Gold Corp
USAU
Verb Technology
VERB
VerifyMe
VRME
Versus Systems Inc.
VRSSF
Vertex Energy
VTNR
Village Farms
VFF.TO
VIQ Solutions
VQS.V
VirTra, Inc.
VTSI
Vision Marine Technologies, Inc.
PRIVATE
VistaGen Therapeutics
VTGN
Volition RX Ltd
VNRX
Vox Royalty
VOX.V
Voyager Digital (Canada) Ltd
VYGVF
Vuzix Corporation
VUZI
Wandisco
WANSF
WeedMD
WMD.V
WELL Health Technologies
WELL.TO
Weyland Tech
WEYL
WidePoint Corporation
WYY
Xinyuan Real Estate
XIN
Xpel Inc
XPEL
Yield10 Bioscience, Inc.
YTEN
ZAGG Inc
ZAGG
Zedge, Inc.
ZDGE
Zoom Telephonics
ZMTP
About LD Micro

Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space. The upcoming "500" in September is the Company's most ambitious project yet, and the first event that can be accessed by anyone. For those interested in attending, please contact David Scher at [e-mail] or visit www.ldmicro.com for more information.

SOURCE: LD Micro



View source version on accesswire.com:
https://www.accesswire.com/600378/LD-Micro--Announces-Preliminary-List-of-Presenters-for-the-LD-500

[BluSkies]

Ok time to keep nasdaq compliance. Have we heard anything on their plans?

[Viewmont]

AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements
NEW YORK, Aug. 3, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that on July 31, 2020, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market under Listing Rule 5550(a)(2). The Company regained compliance with the NASDAQ's requirements when the closing bid price for the Company's common stock was at or above $1.00 for ten consecutive business days.


About AIkido

AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.

[Flexplate]

OMG!!! Kicking myself in the butt for this one lol. I owned tons of shares in this back when it was SPEX I think it was. I sold and gave up on it lol a week later the ticker changed to AIKI now the share price is way up from when I had it lol. Well you live and you learn.

[Taurus69]

$aiki $1.11 v -0.04 (-3.48%)
Volume: 3,887,795 @07/31/20 7:59:52 PM EDT

[Viewmont]

A good PR and news on AIKI should be delivered next week! IMO.
It's been a while we hear directly from AIKI.

[Viewmont]

NEWS! Hoth Therapeutics Executes Licensing Agreement of VNLG-152 for Treatment of Dermatological Diseases
Hoth to receive equity stake in Isoprene, full license of VNLG-152 and royalties from Isoprene for all other fields including Oncology
NEW YORK, July 31, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed a licensing agreement with Isoprene Pharmaceuticals, Inc. to acquire the rights to VNLG-152, a novel retinamides (Retinoic acid metabolism blocking agents, or RAMBAs) for the treatment of dermatological diseases. Isoprene is a cancer therapeutic company that is a University of Maryland, Baltimore New Venture Initiative start-up.


This agreement, which formalizes the previously announced Letter of Intent between the two companies, will also grant Hoth royalty payments from Isoprene for any use of its VNLG-152 including Oncology.

Researchers at the University of Maryland Baltimore discovered novel retinamide RAMBAs and validated their therapeutic utility in animal models of breast and prostate cancer. RAMBAs inhibit the cellular enzyme that metabolizes all-trans retinoic acid (ATRA), which actively directs cells to mature in a controlled manner to ensure normal growth.

In addition to enhancing the beneficial effects of ATRA, the mechanism of action for these RAMBAs has been shown to involve degradation of Mnk 1/2 and suppression of the oncogenic eIF4E pathway. For potential use in treating dermatological conditions, UMB researchers obtained promising early results demonstrating that lead retinamide RAMBAs have equal or superior effects over approved retinoids (ATRA and 13-CRA) to inhibit proliferation of normal human adult keratinocytes and sebocytes, and antikeratinizing effects in reconstructed human epidermis. Initial toxicity profiles for a panel of RAMBAs [Njar et al., 2006] also showed good indications for safe therapeutic use.

These novel RAMBAs block the normal metabolism of endogenous ATRA in cells, increasing the beneficial effects of ATRA. They provide a unique approach to achieve the therapeutic benefit of retinoid therapy while potentially circumventing the adverse events associated with it, a very important property for application to dermatology therapy. ATRA deficiencies are associated with dermatological diseases (acne and psoriasis), and retinoid derivatives have been one of the mainstay therapies for acne. Liarozole is in clinical use for the treatment of psoriasis and ichthyosis. Dermatological retinoid deficiencies are characterized by hyperkeratinization and desquamation and include diseases such as acne, eczema, psoriasis, cold sores, wounds, burns, sunburn, ichthyosis, skin cancer, and Kaposi's Sarcoma, all of which are plausible targets for retinamide RAMBA therapy.

Mr. Robb Knie, Chief Executive Officer of Hoth, commented, "Hoth is pleased to finalize this licensing agreement of a novel therapy that has shown such promise in targeting such a wide array of dermatological afflictions. This latest license agreement reinforces Hoth's commitment to developing novel therapies for multiple skin diseases."

About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

[georgie18]

AIKI...$1.28...in the P/M...

[$oldier Hard]

Got a starter in $AIKI today.

[Viewmont]

Hopefully an up day tomorrow?

[Viewmont]

We should be hearing a follow up update from the following news/pr! IMO. https://www.otcmarkets.com/stock/AIKI/news/story?e&id=1641643

[Viewmont]

https://www.tradingview.com/symbols/NASDAQ-AIKI/technicals/

[Viewmont]

https://www.barchart.com/stocks/quotes/AIKI/opinion

[Viewmont]

Yup!

[mining101]

We will see...

[Icanslim]

Thanks starkd.

[starkd748]

Its means dilution for a quick cash infusion

[Icanslim]

Great point

[Icanslim]

Offerings not always bad, correct? Or too risky to hold through one?

[starkd748]

The chart its below the 50 ma....Which means it cant hold gains...An offering must be coming

[Icanslim]

what do you not like about this penny? Thanks in advance.

[tickersym]

Great Loading time on the DIP!

GLTA

[TrendTrade2016]

should have listened...
TrendTrade2016 Monday, 07/20/20 05:15:21 AM
Re: None 0
Post #
7916
of 7995
AIKI IS GARBAGE STAY AWAY!!

[starkd748]

Longterm is its barely above the 50ma